Ai Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ai Zhang has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Dandan Ju
Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China
1 shared publication - Qin Yang
State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, P.R. China
1 shared publication - Wei He
Department of Respiratory Medicine, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai, China
1 shared publication - Xin Xing
Department of Obstetrics and Gynecology, Fengxian Hospital, Shanghai 201499, China
1 shared publication - Zhijun Jie
Department of Pulmonary and Critical Care Medicine, Shanghai Fifth People's Hospital, Fudan University, Shanghai 200240, China
1 shared publication
Latest Publications
- Open Access
- 23 October 2018
- Published by Wiley in Cancer Medicine
- Vol. 7 (11) , 5716-5726
Aberrant CpG‐methylation affects genes expression predicting survival in lung adenocarcinoma
Lung adenocarcinoma (LUAD) is a common diagnosed disease with high‐mortality rate, and its prognostic implications are under discovered. DNA methylation aberrations are not only an important event for dysregulation of gene expression during tumorigenesis but also a revolution in epigenetics by identifying key prognostic biomarkers for multiple cancers. In this study, we analyzed methylation status of 485 578 CpG sites and RNA‐seq transcriptomes of 20 532 genes for 1095 LUAD samples in TCGA database. The association between DNA methylation and the prognostic value of the corresponding gene expression was identified as well. In total, ten aberrantly methylated and dysregulated genes (AURKA, BLK, CNTN2, HMGA1, PTTG1, TNS4, DAPK2, MFSD2A, THSD1, and WNT7A) were highlighted which were significantly correlated with overall survival of 492 LUAD patients, which were all reported as tumor‐associated genes in other various cancers and worthy of further investigated and might be used as therapeutic targets for LUAD. Together, methylation aberrances regulate gene expression level during tumorigenesis and influence prognosis of LUAD patients. Integrating knowledge of epigenetics and expression of genes can be useful for an in‐depth understanding of cancer mechanism and for the eventual purpose of precisely prognostic and therapeutic target verification.
- 23 October 2018
- Published by Wiley in Cancer Medicine
- Vol. 7 (11) , 5716-5726
Open AccessAberrant CpG‐methylation affects genes expression predicting survival in lung adenocarcinoma
Lung adenocarcinoma (LUAD) is a common diagnosed disease with high‐mortality rate, and its prognostic implications are under discovered. DNA methylation aberrations are not only an important event for dysregulation of gene expression during tumorigenesis but also a revolution in epigenetics by identifying key prognostic biomarkers for multiple cancers. In this study, we analyzed methylation status of 485 578 CpG sites and RNA‐seq transcriptomes of 20 532 genes for 1095 LUAD samples in TCGA database. The association between DNA methylation and the prognostic value of the corresponding gene expression was identified as well. In total, ten aberrantly methylated and dysregulated genes (AURKA, BLK, CNTN2, HMGA1, PTTG1, TNS4, DAPK2, MFSD2A, THSD1, and WNT7A) were highlighted which were significantly correlated with overall survival of 492 LUAD patients, which were all reported as tumor‐associated genes in other various cancers and worthy of further investigated and might be used as therapeutic targets for LUAD. Together, methylation aberrances regulate gene expression level during tumorigenesis and influence prognosis of LUAD patients. Integrating knowledge of epigenetics and expression of genes can be useful for an in‐depth understanding of cancer mechanism and for the eventual purpose of precisely prognostic and therapeutic target verification.